Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt

Journal of Cellular Physiology

Volumn 222, Issue 2, 2010, Pages 433-443

  D'Anneo, Antonella ^a   Augello, Giuseppa ^a   Santulli, Andrea ^a   Giuliano, Michela ^a   Di Fiore, Riccardo ^a   Messina, Concetta ^a   Tesoriere, Giovanni ^a   Vento, Renza ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LAPACHONE; CASPASE 3; CASPASE 6; INHIBITOR OF APOPTOSIS PROTEIN; LAMIN B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BID; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; WORTMANNIN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; BETA-LAPACHONE; BID PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASP6 PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; NAPHTHOQUINONE; PROTEIN KINASE INHIBITOR; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RETINOBLASTOMA; ACTIVE TRANSPORT; CELL NUCLEUS; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TIME; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASPASE 3; CASPASE 6; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LAMIN TYPE B; NAPHTHOQUINONES; PACLITAXEL; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73349137659     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21983     Document Type: Article

References (48)

1. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. 1984. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology 91:1351-1355.
2. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F, Desjardins L. 2006. Retinoblastoma. Orphanet J Rare Dis 1:1-11.
3. Antoneli CB, Ribeiro KC, Steinhorst F, Novaes PE, Chojniak MM, Malogolowkin M. 2006. Treatment of retinoblastoma patients with chemoreduction plus local therapy: Experience of the AC Camargo Hospital, Brazil. J Pediatr Hematol Oncol 28:342-345.
4. Calvaruso G, Carabillò M, Giuliano M, Lauricella M, D'Anneo A, Vento R, Tesoriere G. 2001. Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: The effect of combined treatment with the topoisomerase I-inhibitor topotecan. Int J Oncol 18:1233-1237.
5. Cantley LC, Neel BG. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96:4240-4245.
6. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. 1983. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779-784.
7. Chakravarti A, Heydon K, Wu CL, Hammond E, Pollack A, Roach M, Wolkov H, Okunieff P, Cox J, Fontanesi J, Abrams R, Pilepich M, Shipley W. 2003. Loss of p16 expression is of prognostic J significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group Protocol 86-10. J Clin Oncol 21:3328-3334.
8. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. 2004. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11:915-923.
9. Chène P. 2004. Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface. Mol Cancer Res 2:20-28.
10. Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R. 2007. Retinoblastoma: Review of current management. Oncologist 12:1237-1246.
11. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
12. Classon M, Harlow E. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2:910-917.
13. Di Felice V, Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G. 1998. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. Int J Oncol 13:225-232.
14. Drago-Ferrante R, Santulli A, Di Fiore R, Giuliano M, Calvaruso G, Tesoriere G, Vento R. 2008. Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1. Int J Oncol 33:677-687.
15. Duckett CS. 2005. IAP proteins: Sticking it to Smac. Biochem J 1:385.
16. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. 2003. PI3K/Akt and apoptosis: Size matters. Oncogene 22:8983-8998.
17. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646.
18. Giacinti C, Giordano A. 2006. RB and cell cycle progression. Oncogene 25:5220-5227.
19. Giuliano M, Vento R, Lauricella M, Calvaruso G, Carabillo M, Tesoriere G. 1996. Role of insulin-like growth factors in autocrine growth of human retinoblastoma Y79 cells. Eur J Biochem 236:523-532.
20. Giuliano M, Lauricella M, Vassallo E, Carabillò M, Vento R, Tesoriere G. 1998. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Invest Ophthalmol Vis Sci 39:1300-1311.
21. Giuliano M, Lauricella M, Calvaruso G, Carabillò M, Emanuele S, Vento R, Tesoriere G. 1999. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 59:5586-5595.
22. Goodrich DW.2006. The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene 25:5233-5243.
23. Hallstrom TC, Mori S, Nevins JR. 2008. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13:11-22.
24. Jason DW, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. 1999. Nucleolar Arf sequesters MDM2 and activates p53. Nat Cell Biol 1:20-26.
25. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Aerts I, Mercier G, Bours D, Desjardins L, Doz F. 2009. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 52:637-643.
26. Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan Z-M. 2007. RING domainmediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res 67:6026-6030.
27. Knudson AG. 1971. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
28. Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, Toillon RA, Oxombre B, Hondermarck H, Le Bourhis X. 2009. Trk A overexpression enhances growth and metastasis of breast cancer cells. Oncogene 28:1960-1970.
29. Lauricella M, Calvaruso G, Giuliano M, Carabillò M, Emanuele S, Vento R, Tesoriere G. 2000. Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells. Tumour Biol 21:337-348.
30. Li CJ, Li YZ, Pinto AV, Pardee AB. 1999. Potent inhibition of tumor survival in vivo by betalapachone plus taxol: Combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA 96:13369-13374.
31. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ. 2003. Selective killing of cancer cells by betalapachone: Direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA 100: 2674-2678.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
33. Marees T, van Leeuwen FE, de Boer MR, Imhof SM, Ringens PJ, Moll AC. 2009. Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer (in press).
34. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. 2007. Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6:609-621.
35. Mayo LD, Donner DB. 2001. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of MDM2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 25:11598-11603.
36. Melamud A, Palekar R, Singh A. 2006. Retinoblastoma. Am Fam Physician 73:1039-1044.
37. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 16:55-63.
38. Nevins J. 2001. The Rb/E2F pathway and cancer. Hum Mol Genet 10:699-703.
39. Pardee AB, Li YZ, Li CJ. 2002. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2:227-242.
40. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. 2000. NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 275:5416-5424.
41. Pozarowski P, Grabarek J, Darzynkiewicz Z. 2003. Flow cytometry of apoptosis. Curr Protoc Cytom Chapter 7: Unit 7.19.
42. Seol D-W. 2008. Up-regulation of IAPs by PI-3K: A cell survival signal-mediated antiapoptotic mechanism. Biochem Biophys Res Commun 377:508-511.
43. Shah HR, Conway RM, Van Quill KR, Madigan MC, Howard SA, Qi J, Weinberg V, O'Brien JM. 2008. Beta-lapachone inhibits proliferation and induces apoptosis in retinoblastoma cell lines. Eye 22:454-460.
44. Vento R, Giuliano M, Lauricella M, Carabillò M, Di Liberto D, Tesoriere G. 1998. Induction of programmed cell death in human retinoblastoma Y79 cells by C2-ceramide. Mol Cell Biochem 185:7-15.
45. Vento R, D'Alessandro N, Giuliano M, Lauricella M, Carabillò M, Tesoriere G. 2000. Induction of apoptosis by arachidonic acid in human retinoblastoma Y79 cells: Involvement of oxidative stress. Exp Eye Res 70:503-517.
46. Wang J, He FT, Tzang CH, Fong WF, Xiao PG, Han R, Yang MS. 2005. Differential gene expression profiles in paclitaxel induced cell cycle arrest and apoptosis in human breast cancer MCF-7 cells. Yao Xue Xue Bao 40:1099-1104.
47. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D.1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 3: 20-26.
48. Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, Stovall M, Fraumeni JF, Jr., Kleinerman RA. 2009. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 101:581-591.